Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Key Points

• The short interest in Daiichi Sankyo Co., Ltd. declined by 24.9% in August, falling to 76,400 shares from 101,700 shares at the end of July.
• Daiichi Sankyo's current stock price is $24.27, with a market cap of $45.98 billion and a price-to-earnings ratio of 23.56.
• Nomura Securities has upgraded Daiichi Sankyo to a "strong-buy" rating, contributing to a consensus rating of "Strong Buy" for the stock.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the target of a large decline in short interest in August. As of August 15th, there was short interest totaling 76,400 shares, a decline of 24.9% from the July 31st total of 101,700 shares. Based on an average daily trading volume, of 394,600 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 394,600 shares, the days-to-cover ratio is presently 0.2 days.

Daiichi Sankyo Price Performance

Shares of DSNKY stock traded down $0.08 during trading on Friday, hitting $23.86. The company had a trading volume of 135,910 shares, compared to its average volume of 229,950. The company has a quick ratio of 1.85, a current ratio of 2.53 and a debt-to-equity ratio of 0.06. The stock's 50-day moving average is $24.22 and its two-hundred day moving average is $24.19. The stock has a market capitalization of $45.20 billion and a price-to-earnings ratio of 23.17. Daiichi Sankyo has a 52 week low of $20.92 and a 52 week high of $36.68.

Wall Street Analyst Weigh In

Separately, Nomura Securities raised Daiichi Sankyo to a "strong-buy" rating in a report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Daiichi Sankyo presently has a consensus rating of "Strong Buy".

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.